Stroke Core Performance Measures Sanford Medical Center Fargo Annual summaries for 2022 through 2024 YTD

Updated: 12/2024

Rates		Measure Description	Year	Rate	(Num/Den)
STK-1	VTE Prophylaxis	Ischemic and hemorrhagic	2022	91%	267/292
		stroke patients who received VTE prophylaxis or have	2023	84%	246/293
		documentation why no VTE	2024	89%	259/291
		prophylaxis was given the day			
		of or the day after hospital			
		admission.			
STK-2	D/C on Antithrombotic Therapy	Ischemic stroke patients	2022	100%	175/175
		prescribed antithrombotic therapy at discharge (e.g.,	2023	100%	167/167
		warfarin, aspirin, other	2024	100%	167/167
		antiplatelet drug).			
STK-3	Anticoagulation Therapy Atrial Fib	Ischemic stroke patients with	2022	100%	36/36
		atrial fibrillation/flutter who	2023	96%	22/23
		are prescribed anticoagulation			
		therapy at hospital discharge.	2024	96%	24/25
STK-4	Thrombolytic Therapy	Acute ischemic stroke patients	2022	100%	11/11
		who arrive at this hospital	2023	100%	6/6
		within 2 hours of time last known well and for whom IV t-	2024	100%	6/6
		PA was initiated at this	202.	20070	0,0
		hospital within 3 hours of time			
		last known well.			
STK-5	Antithrombotic Therapy by the end of hospital day 2	Ischemic stroke patients who	2022	98%	117/120
		receive antithrombotic	2023	99%	141/143
		therapy by the end of hospital day 2.	2024	99%	132/134
STK-6	Discharge on Statin Medication	Ischemic stroke patients who are prescribed statin	2022	98%	163/166
		medication at hospital	2023	99%	170/171
		discharge.	2024	100%	165/165
STK-8	Stroke Education	Ischemic or hemorrhagic	2022	90%	127/141
		stroke patients or their	2021	86%	132/152
		caregivers who were given educational materials during	2020	94%	140/149
		their hospital stay addressing stroke.			
STK-10	Assessed for Rehab	Ischemic or hemorrhagic	2022	99%	272/274
		stroke patients who were	2023	100%	288/288
		assessed for rehabilitation			
		services.	2024	100%	281/282

TJC Comprehensive Stroke Performance Measures HOS-Sanford Medical Center Fargo Annual summaries for 2022 through 2024 YTD

Updated: 12/2024

Rates		Measure Description	Year	Rate	(Num/Den)
CSTK-1	NIHSS Score Performed for Ischemic Stroke Patients	Ischemic stroke patients for	2022	94%	251/266
		whom an initial NIH Stroke	2023	93%	260/279
		Scale score is performed prior	2024	93%	246/264
		to any acute recanalization			
		therapy or within 12 hours of			
		emergency department			
		arrival.			
CSTK-3	Severity Measurement Performed for SAH and	SAH and ICH patients for	2022	93%	79/85
	ICH Patients - Overall	whom a severity	2023	90%	66/73
		measurement (Hunt and Hess	2024	93%	85/91
		or ICH Score) is performed			,-
		prior to surgical intervention			
		or within 6 hours of			
		emergency department			
		arrival.			
CSTK-4	Procoagulant Reversal Agent Initiation for ICH	ICH patients with an INR > 1.4	2022	100%	8/8
		at hospital arrival who are	2023	100%	5/5
		treated with a procoagulant	2024	80%	4/5
		reversal agent.			
CSTK-5	Hemorrhagic Transformation - Overall	Ischemic stroke patients who	2022	16%	14/89
	<u> </u>	develop symptomatic	2023	16%	17/104
		intracranial hemorrhage	2024	12%	11/90
		within 36 hours after	2021	1270	11,50
		treatment with IV t-PA or			
		thrombectomy.			
CSTK-6	Nimodipine Treatment Administered	SAH patients for whom	2022	95%	42/44
		nimodipine treatment was	2023	96%	43/45
		administered within 24 hours	2024	100%	39/39
		of arrival at this hospital.			
CSTK-8	TICI Post-Treatment Reperfusion Grade	Ischemic stroke patients with	2022	96%	64/67
		a posttreatment reperfusion	2023	87%	69/79
		grade of TICI 2B or higher	2024	93%	62/67
		after thrombectomy.			,
Datas			W	9.0 - di	# 0
Rates Continuou	us Measures:		Year	Median	# Cases
CSTK-9	Arrival Time to Skin Pupncture				
	·		2022	53	59
			2023	43.5	68
			2024	56	56

TJC Comprehensive Stroke Performance Measures

HOS-Sanford Medical Center Fargo Annual summaries for 2022 through 2024 YTD

Updated: 12/2024

Rates		Measure Description	Year	Rate	(Num/Den)
CSTK-10	Modified Rankin Score (mRS) at 90 Days: Favorable Outcome (Overall)	Patients who received IV t-PA and/or mechanical	2022	43%	33/76
			2023	35%	35/100
		endovascular reperfusion and	2024	33%	16/48
		have a modified Rankin Scale			
		2 at 90 days.			
CSTK-11	or Higher mechanical endovasc reperfusion within 12	Patients with an LVO received	2022	91%	51/56
		mechanical endovascular	2023	76%	45/59
		reperfusion within 120	2024	87%	45/52
		minutes of arrival and have a			
		TICI 2B or higher.			
CSTK-12	TICI 2B or Higher	Patients with an LVO received	2022	84%	51/61
		mechanical endovascular	2023	78%	50/64
		reperfusion and a TICI 2B or	2024	92%	55/60
		higher within 60 minute of skin puncture.			